Blood biomarkers for evaluation of perinatal encephalopathy: state of the art.
Current Opinion in Pediatrics. 2018-04-01; 30(2): 199-203
DOI: 10.1097/mop.0000000000000591
Lire sur PubMed
1. Curr Opin Pediatr. 2018 Apr;30(2):199-203. doi: 10.1097/MOP.0000000000000591.
Blood biomarkers for evaluation of perinatal encephalopathy: state of the art.
Graham EM(1)(2), Everett AD(2)(3), Delpech JC(4), Northington FJ(2)(5).
Author information:
(1)Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics.
(2)Neurosciences Intensive Care Nursery program.
(3)Division of Cardiology, Department of Pediatrics, Johns Hopkins University
School of Medicine, Baltimore, Maryland.
(4)Department of Newborn Medicine, Boston Children’s Hospital, Harvard Medical
School, Boston, Massachusetts.
(5)Division of Neonatology, Department of Pediatrics, Johns Hopkins University
School of Medicine, Baltimore, Maryland, USA.
PURPOSE OF REVIEW: The rapid progress in biomarker science is on the threshold of
significantly changing clinical care for infants in the neonatal ICU. Infants
with neonatal brain injuries will likely be the first group whose management is
dramatically altered with point-of-care, rapidly available brain biomarker
analysis. Providing an interim update on progress in this area is the purpose of
this review.
RECENT FINDINGS: Highlighted findings from the past 18 months of publications on
biomarkers in neonatal brain injury include; Specific nonbrain markers of cardiac
health and global asphyxia continue to provide information on brain injury after
hypoxic-ischemic encephalopathy (HIE). Prediction of injury in the piglet
hypoxia-ischemia model is improved with the use of a combination score of plasma
metabolites. In a neonatal piglet model of perinatal hypoxia-ischemia, a systemic
proinflammatory surge of cytokines has been identified after rewarming from
therapeutic hypothermia. New biomarkers identified recently include osteopontin,
activin A, neutrophil gelatinase-associated lipocalin, secretoneurin, Tau and
neurofilament light protein. Brain-based biomarkers differ in their ability to
predict short-term in-hospital outcomes and long-term neurologic deficits.
SUMMARY: Neonatal brain biomarker research is currently in its very early
development with major advances still to be made.
DOI: 10.1097/MOP.0000000000000591
PMCID: PMC5884146
PMID: 29346139 [Indexed for MEDLINE]